Benjamin F. Edwards & Company’s Neurocrine Biosciences NBIX Stock Holding History

Benjamin F. Edwards & Company’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$31K	Buy	226 +7	+3%	+$960	﹤0.01%	1444
2024 Q1	$30K	Sell	219 -28	-11%	-$3.82K	﹤0.01%	1424
2023 Q4	$33K	Buy	+247	New	+$28.4K	﹤0.01%	1364
2023 Q1	–	Sell	-2,646	Closed	-$316K	–	1867
2022 Q4	$316K	Buy	+2,646	New	+$310K	0.01%	588
2022 Q3	–	Sell	-46	Closed	-$4K	–	1879
2022 Q2	$4K	Buy	+46	New	+$4.25K	﹤0.01%	1592
2021 Q4	–	Sell	-100	Closed	-$10K	–	1748
2021 Q3	$10K	Hold	100	–	–	﹤0.01%	1379
2021 Q2	$10K	Hold	100	–	–	﹤0.01%	1382
2021 Q1	$10K	Hold	100	–	–	﹤0.01%	1362
2020 Q4	$10K	Hold	100	–	–	﹤0.01%	1279
2020 Q3	$10K	Hold	100	–	–	﹤0.01%	1278
2020 Q2	$12K	Hold	100	–	–	﹤0.01%	1243
2020 Q1	$9K	Hold	100	–	–	﹤0.01%	1300
2019 Q4	$11K	Hold	100	–	–	﹤0.01%	1407
2019 Q3	$9K	Hold	100	–	–	﹤0.01%	1442
2019 Q2	$8K	Buy	+100	New	+$8.21K	﹤0.01%	1489

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Benjamin F. Edwards & Company's NBIX Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its Neurocrine Biosciences (NBIX) stake by 3.2% in Q2 2024, buying an estimated $960 and bringing the position to 226 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #1444.

Benjamin F. Edwards & Company first reported a position in NBIX in Q2 2019 and has held it in 15 quarters since. The position peaked at $316K in Q4 2022. 595 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

Benjamin F. Edwards & Company held 226 shares of Neurocrine Biosciences worth $31K as of Q2 2024.
Benjamin F. Edwards & Company bought 7 Neurocrine Biosciences shares in Q2 2024, an estimated $960.
Neurocrine Biosciences made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1444 holding.
Benjamin F. Edwards & Company first reported a position in Neurocrine Biosciences in Q2 2019 and has held it in 15 quarters since.
Benjamin F. Edwards & Company's Neurocrine Biosciences position peaked at $316K in Q4 2022.
595 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.